ApoE genotype-specific inhibition of apoptosis

Journal of Lipid Research

Volumn 44, Issue 8, 2003, Pages 1566-1573

  DeKroon, Robert M ^a   Mihovilovic, Mirta ^a   Goodger, Zoe V ^a   Robinette, Jennifer B ^a   Sullivan, Patrick M ^a   Saunders, Ann M ^a,b   Strittmatter, Warren J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Apolipoprotein E; Atherosclerosis; Endothelial cell; High density lipoprotein; Low density lipoprotein; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CASPASE 3; CASPASE 7; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENOTYPE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; UMBILICAL VEIN;

APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; APOPTOSIS; CASPASES; CELL LINE; CHOLESTEROL, HDL; GENOTYPE; HUMANS; LIPOPROTEINS, VLDL; LYSOPHOSPHOLIPIDS;

EID: 0142105901     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300097-JLR200     Document Type: Article

References (30)

1. Varani, J., M. K. Dame, C. G. Taylor, V. Sarma, R. Merino, R. G. Kunkel, G. Nunez, and V. M. Dixit. 1995. Age-dependent injury in human umbilical vein endothelial cells: relationship to apoptosis and correlation with a lack of A20 expression. Lab. Invest. 73: 851-858.
2. Dimmeler, S., and A. M. Zeiher. 2000. Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. Regul. Pept. 90: 19-25.
3. Martinet, W., and M. M. Kockx. 2001. Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation. Curr. Opin. Lipidol. 12: 535-541.
4. Hermann, C., B. Assmus, C. Urbich, A. M. Zeiher, and S. Dimmeler. 2000. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20: 402-409.
5. Ho, F. M., S. H. Liu, C. S. Liau, P. J. Huang, S. G. Shiah, and S. Y. Lin-Shiau. 1999. Nitric oxide prevents apoptosis of human endothelial cells from high glucose exposure during early stage. J. Cell. Biochem. 75: 258-263.
6. Cid, M. C., H. W. Schnaper, and H. K. Kleinman. 2002. Estrogens and the vascular endothelium. Ann. N. Y. Acad. Sci. 966: 143-157.
7. Nofer, J. R., B. Levkau, I. Wolinska, R. Junker, M. Fobker, A. von Eckardstein, U. Seedorf, and G. Assmann. 2001. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276: 34480-34485.
8. Morales-Ruiz, M., M.J. Lee, S. Zollner, J. P. Gratton, R. Scotland, I. Shiojima, K. Walsh, T. Hla, and W. C. Sessa. 2001. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J. Biol. Chem. 276: 19672-19677.
9. Mahley, R. W., and Y. Huang. 1999. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr. Opin. Lipidol. 10: 207-217.
10. Mahley, R. W., Y. Huang, and S. C. Rall, Jr. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid Res. 40: 1933-1949.
11. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
12. Bohnet, K., T. Pillot, S. Visvikis, N. Sabolovic, and G. Siest. 1996. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J. Lipid Res. 37: 1316-1324.
13. Knouff, C., M. E. Hinsdale, H. Mezdour, M. K. Altenburg, M. Watanabe, S. H. Quarfordt, P. M. Sullivan, and N. Maeda. 1999. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103: 1579-1586.
14. Weisgraber, K. H. 1994. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45: 249-302.
15. Utermann, G. 1985. Genetic polymorphism of apolipoprotein E-impact on plasma lipoprotein metabolism. In Diabetes, Obesity and Hyperlipidemias. Vol. 3. G. Crepaldi, A. Tiengo, and G. Baggio, editors. Elsevier Science, Amsterdam. 1-28.
16. Utermann, G. 1982. Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III). Ric. Clin. Lab. 12: 23-30.
17. Xu, P. T., D. Schmechel, T. Rothrock-Christian, D. S. Burkhart, H. L. Qiu, B. Popko, P. Sullivan, N. Maeda, A. M. Saunders, A. D. Roses, and J. R. Gilbert. 1996. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice 2. Neurobiol. Dis. 3: 229-245.
18. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 3: 1345-1353.
19. Ordovas, J. M. 1998. Separation of apolipoproteins by polyacrylamide gel electrophoresis. Methods Mol. Biol. 110: 93-103.
20. Sullivan, P. M., H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R. L. Reddick, S. H. Quarfordt, and N. Maeda. 1997. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272: 17972-17980.
21. Sullivan, P. M., H. Mezdour, S. H. Quarfordt, and N. Maeda. 1998. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse ApoE with human ApoE*2. J. Clin. Invest. 102: 130-135.
22. Willnow, T. E., J. L. Goldstein, K. Orth, M. S. Brown, and J. Herz. 1992. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance 1.J. Biol. Chem. 267: 26172-26180.
23. Strittmatter, W. J., K. H. Weisgraber, D. Y. Huang, L. M. Dong, G. S. Salvesen, M. Pericak-Vance, D. Schmechel, A. M. Saunders, D. Goldgaber, and A. D. Roses. 1993. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90: 8098-8102.
24. Saunders, A. M., W. J. Strittmatter, D. Schmechel, P. H. George-Hyslop, M. A. Pericak-Vance, S. H. Joo, B. L. Rosi, J. F. Gusella, D. R. Crapper-MacLachlan, and M. J. Alberts. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43: 1467-1472.
25. Corder, E. H., A. M. Saunders, W.J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, and M. A. Pericak-Vance. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261: 921-923.
26. Thompson, C. B. 1995. Apoptosis in the pathogenesis and treatment of disease. Science. 267: 1456-1462.
27. Koch, S., N. Donarski, K. Goetze, M. Kreckel, H.J. Stuerenburg, C. Buhmann, and U. Beisiegel. 2001. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42: 1143-1151.
28. Guyton, J. R., S. E. Miller, M. E. Martin, W. A. Khan, A. D. Roses, and W. J. Strittmatter. 1998. Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid 3. J. Neurochem. 70: 1235-1240.
29. Rebeck, G. W., N. C. Alonzo, O. Berezovska, S. D. Harr, R. B. Knowles, J. H. Growdon, B. T. Hyman, and A. J. Mendez. 1998. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp. Neurol. 149: 175-182.
30. Montine, K. S., C. N. Bassett, J. J. Ou, W. R. Markesbery, L. L. Swift, and T. J. Montine. 1998. Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins. J. Lipid Res. 39: 2443-2451.